Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Patients With Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma and Other Forms of Non-Hodgkin's Lymphoma

NCT02564744 is registered in ClinicalTrials.gov with Debiopharm International SA as lead sponsor.

NCT NCT02564744
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02564744 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Patients With Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma and Other Forms of Non-Hodgkin's Lymphoma
Lead sponsor
Debiopharm International SA
Phase
Phase 2
Overall status
Completed
Start date
June 5, 2016
Completion date
June 25, 2021
Enrollment
100 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell non-hodgkin's lymphoma, diffuse large b-cell lymphoma